The Aplastic Anemia drugs in development market research report provides comprehensive information on the therapeutics under development for Aplastic Anemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Aplastic Anemia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Aplastic Anemia and features dormant and discontinued products.

GlobalData tracks 16 drugs in development for Aplastic Anemia by 16 companies/universities/institutes. The top development phase for Aplastic Anemia is preclinical with seven drugs in that stage. The Aplastic Anemia pipeline has 14 drugs in development by companies and two by universities/ institutes. Some of the companies in the Aplastic Anemia pipeline products market are: Cell Source, Regen BioPharma and Ono Pharmaceutical.

The key targets in the Aplastic Anemia pipeline products market include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL), Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49), and Sphingosine 1-Phosphate Receptor 5 (Endothelial Differentiation G Protein Coupled Receptor 8 or Sphingosine 1 Phosphate Receptor Edg 8 or S1PR5).

The key mechanisms of action in the Aplastic Anemia pipeline product include Thrombopoietin Receptor (Myeloproliferative Leukemia Protein or Proto Oncogene c Mpl or CD110 or MPL) Agonist with two drugs in Filing rejected/Withdrawn. The Aplastic Anemia pipeline products include four routes of administration with the top ROA being Intravenous and seven key molecule types in the Aplastic Anemia pipeline products market including Cell Therapy, and Small Molecule.

Aplastic Anemia overview

Aplastic anemia is a syndrome of bone marrow failure characterized by peripheral pancytopenia and marrow hypoplasia. Symptoms include fatigue, pale skin, rapid or irregular heart rate, shortness of breath with exertion, nosebleeds and bleeding gums, prolonged bleeding from cuts, skin rash, dizziness, and headache. Risk factors include exposure to toxic chemicals, treatment with high-dose radiation or chemotherapy for cancer, certain blood diseases, autoimmune disorders, and serious infections. Treatment includes immunosuppressants and stem cell transplant.

For a complete picture of Aplastic Anemia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.